RecruitingNCT07614776
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
PHASE3 · 304 planned enrolment
- Countries listed
- 7
- Registry update
- September 29, 2026
